Volume 13 Supplement 4
Cross-sectional study of HIV living people cohort to specify indications to antiretroviral treatment in naïve patients
© Pronin and Kaminskiy; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Purpose of the study
To determine groups in HIV living people cohort in the aspect of further HAART.
The data on 2271 patients was investigated in a cross-sectional study. All patients at the moment of survey had no attributes of clinical progression of disease and did not receive HAART. Clinical exam and blood sampling was performed, in blood specimens HIV virus load (PCR m2000rt Abbott Biosystems analyzer, RealTime HIV-1 sets) and CD3+CD4+ and CD3+CD4- phenotypes of T-lymphocytes were analyzed (flow cytometer BD FACSCount, sets of antibodies TriTEST CD3/CD4/CD45). For 363 patients additionally CD3+CD8+ and CD3+CD4-CD8- (double negative) phenotypes of T-lymphocytes were determined. Duration of HIV infection and the age of the patient was also included into analysis. Received data was processed statistically by means of SPSS software.
Summary of results
Viral Load (log 10 copies/ml)
Disease Duration (years)
Temporary No Progressors
Permanently No Progressors
HIV Infected Total
1. Evaluation of no progressive status (temporary or permanent) as well as diagnostics of the progressive state outlines indications to antiretroviral treatment. 2. Evaluated internal groups support approach to start HAART after CD4 cell counts are less than 500/mm3 and the depletion level of 350 CD4 cells/mm3 lies in the middle scope of progressive group.
- Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009, 373 (9672): 1352-1363. 10.1016/S0140-6736(09)60612-7. April 18Google Scholar
- O'Connell KA, Bailey JR, Blankson JN: Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci. 2009, 30 (12): 631-7. 10.1016/j.tips.2009.09.005. DecView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.